A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with
relapse/refactory diffuse large B-cell lymphoma who have received at least 2 lines of
therapeutic schedules including rituximab. TQ-B3525 tablet administered 20mg orally, once
daily in 28-day cycle.